Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

Lumos Diagnostics Holdings Ltd (ASX:LDX) is set to see its point-of-care respiratory test FebriDx made available to a large audience in the United States, through the awarding of a national contract with MediGroup.

The FebriDx test provides results within 10 minutes, based on a fingerstick blood sample.

Its elevation to a national contract with MediGroup follows a decision from the US Food and Drug Administration (FDA) in July 2023 to clear it for marketing as a product to help diagnose bacterial acute respiratory infection and to differentiate from non-bacterial etiology.

The clearance was based on the presumption of its use by medical professionals and with patients in emergency or urgent care scenarios, and this meshes well with MediGroup, whose members include surgical clinics, non-acute care facilities and physician offices throughout the United States.

Lumos CEO and managing director Doug Ward said he was pleased to see FebriDx added to MedGroup’s national contract.

“As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations,” he said.

“This is a key relationship for us as we continue to build out our distribution coverage for FebriDx.”

Lumos shares rose on the news, and at 13:53 AEDT, they were trading at 3.7 cents – an increase of 10.29% since the market opened.

Join the discussion: See what HotCopper users are saying about Lumos Diagnostics and be part of the conversations that move the markets.